Total Payments
$21,269
2024 Payments
$3,049
Companies
67
Transactions
360
Medicare Patients
868
Medicare Billing
$182,705
Payment Breakdown by Category
Consulting$11,676 (54.9%)
Food & Beverage$8,323 (39.1%)
Education$982.29 (4.6%)
Travel$287.54 (1.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,676 | 5 | 54.9% |
| Food and Beverage | $8,323 | 337 | 39.1% |
| Education | $982.29 | 15 | 4.6% |
| Travel and Lodging | $287.54 | 3 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,867 | 28 | $0 (2024) |
| Celgene Corporation | $4,020 | 19 | $0 (2024) |
| Janssen Biotech, Inc. | $2,777 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,011 | 11 | $0 (2023) |
| PFIZER INC. | $706.00 | 31 | $0 (2024) |
| Incyte Corporation | $565.12 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $472.21 | 9 | $0 (2024) |
| Seagen Inc. | $390.79 | 11 | $0 (2023) |
| Lilly USA, LLC | $358.38 | 10 | $0 (2024) |
| GENZYME CORPORATION | $328.35 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,049 | 118 | PFIZER INC. ($408.38) |
| 2023 | $5,202 | 154 | E.R. Squibb & Sons, L.L.C. ($1,781) |
| 2022 | $1,898 | 65 | Astellas Pharma US Inc ($235.71) |
| 2021 | $110.59 | 2 | Inari Medical, Inc. ($97.30) |
| 2019 | $10,228 | 16 | AstraZeneca Pharmaceuticals LP ($4,392) |
| 2018 | $70.87 | 1 | E.R. Squibb & Sons, L.L.C. ($70.87) |
| 2017 | $710.14 | 4 | Celgene Corporation ($500.00) |
All Payment Transactions
360 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: NONE | ||||||
| 12/09/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.56 | General |
| Category: Hematology/Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $24.44 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $2.56 | General |
| Category: Oncology | ||||||
| 12/03/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $26.88 | General |
| Category: Hematology | ||||||
| 11/20/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.73 | General |
| 11/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $39.51 | General |
| Category: Oncology | ||||||
| 11/06/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.89 | General |
| 11/05/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.90 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | INOGEN, INC. | INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH (Device) | Food and Beverage | Cash or cash equivalent | $23.81 | General |
| Category: OXYGEN CONCENTRATOR | ||||||
| 10/29/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: Oncology | ||||||
| 10/24/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $42.74 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $9.76 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $28.44 | General |
| Category: NONE | ||||||
| 10/07/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $32.32 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 85 | 171 | $33,002 | $11,372 |
| 2021 | 5 | 377 | 865 | $375,168 | $95,674 |
| 2020 | 6 | 406 | 902 | $318,963 | $75,659 |
Total Patients
868
Total Services
1,938
Medicare Billing
$182,705
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 62 | $16,273 | $5,724 | 35.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 31 | $6,220 | $2,111 | 33.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $5,047 | $1,569 | 31.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,674 | $1,539 | 32.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 16 | 54 | $788.45 | $428.40 | 54.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 220 | 663 | $294,846 | $72,715 | 24.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 60 | 66 | $33,273 | $10,204 | 30.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 50 | 50 | $27,706 | $7,374 | 26.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 63 | $16,352 | $5,265 | 32.2% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Facility | 2021 | 15 | 23 | $2,991 | $116.16 | 3.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 209 | 624 | $228,352 | $52,309 | 22.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 47 | 57 | $29,526 | $9,382 | 31.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 51 | 51 | $26,371 | $5,864 | 22.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 66 | $17,556 | $5,595 | 31.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 43 | 52 | $14,196 | $2,158 | 15.2% |
| 99211 | Established patient office or other outpatient visit, typically 5 minutes | Facility | 2020 | 25 | 52 | $2,962 | $351.17 | 11.9% |
About Dr. Kamal Sharma, D.O
Dr. Kamal Sharma, D.O is a Hematology & Oncology healthcare provider based in Lakeland, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093914988.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kamal Sharma, D.O has received a total of $21,269 in payments from pharmaceutical and medical device companies, with $3,049 received in 2024. These payments were reported across 360 transactions from 67 companies. The most common payment nature is "Consulting Fee" ($11,676).
As a Medicare-enrolled provider, Sharma has provided services to 868 Medicare beneficiaries, totaling 1,938 services with total Medicare billing of $182,705. Data is available for 3 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Lakeland, FL
- Active Since 07/12/2007
- Last Updated 01/03/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093914988
Products in Payments
- CALQUENCE (Drug) $4,471
- Revlimid (Drug) $3,665
- IMBRUVICA (Drug) $2,541
- KEYTRUDA (Biological) $267.05
- VERZENIO (Drug) $230.81
- Enhertu (Drug) $228.99
- REBLOZYL (Biological) $227.65
- JAKAFI (Drug) $227.58
- ZEPZELCA (Drug) $192.91
- ENHERTU (Biological) $188.31
- SARCLISA (Biological) $181.70
- OPDIVO (Biological) $162.26
- IBRANCE (Drug) $158.27
- INLYTA (Drug) $158.07
- KISQALI (Drug) $156.00
- Nubeqa (Drug) $141.44
- DARZALEX (Biological) $133.23
- ADCETRIS (Biological) $128.08
- Pomalyst (Drug) $127.15
- KRAZATI (Drug) $127.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Lakeland
Dr. Sushma Nakka, Md, MD
Hematology & Oncology — Payments: $45,764
Hematology & Oncology $45,764
Dr. Imran Ahmad, Md, MD
Hematology & Oncology — Payments: $2,408
Hematology & Oncology $2,408
Kamal Haider, M.d, M.D
Hematology & Oncology — Payments: $2,189
Hematology & Oncology $2,189
Antonio Trindade, M.d, M.D
Hematology & Oncology
Hematology & Oncology